246 related articles for article (PubMed ID: 18494752)
1. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.
Stam WB; Aversa F; Kumar RN; Jansen JP
Value Health; 2008; 11(5):830-41. PubMed ID: 18494752
[TBL] [Abstract][Full Text] [Related]
2. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
Bruynesteyn K; Gant V; McKenzie C; Pagliuca T; Poynton C; Kumar RN; Jansen JP
Eur J Haematol; 2007 Jun; 78(6):532-9. PubMed ID: 17419744
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden.
Naik S; Lundberg J; Kumar R; Sjolin J; Jansen JP
Scand J Infect Dis; 2011 Jul; 43(6-7):504-14. PubMed ID: 21332286
[TBL] [Abstract][Full Text] [Related]
4. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia.
Al-Badriyeh D; Liew D; Stewart K; Kong DC
J Antimicrob Chemother; 2009 Jun; 63(6):1276-85. PubMed ID: 19346292
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever.
Wingard JR; Leather HL; Wood CA; Gerth WC; Lupinacci RJ; Berger ML; Mansley EC
Am J Health Syst Pharm; 2007 Mar; 64(6):637-43. PubMed ID: 17353573
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
7. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.
Maertens JA; Madero L; Reilly AF; Lehrnbecher T; Groll AH; Jafri HS; Green M; Nania JJ; Bourque MR; Wise BA; Strohmaier KM; Taylor AF; Kartsonis NA; Chow JW; Arndt CA; DePauw BE; Walsh TJ;
Pediatr Infect Dis J; 2010 May; 29(5):415-20. PubMed ID: 20431381
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia.
Al-Badriyeh D; Liew D; Stewart K; Kong DC
Mycoses; 2012 May; 55(3):244-56. PubMed ID: 21790799
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomic evaluation of caspofungin versus liposomal amphotericin B in empirical treatment of invasive fungal infections in Turkey.
Turner SJ; Senol E; Kara A; Al-Badriyeh D; Kong DC; Dinleyici EC
Int J Antimicrob Agents; 2013 Sep; 42(3):276-80. PubMed ID: 23830892
[TBL] [Abstract][Full Text] [Related]
11. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
12. Caspofungin versus liposomal amphotericin B: are they really comparable?
Sekine L; Humbwavali J; Wolff FH; Barcellos NT
Pediatr Infect Dis J; 2010 Oct; 29(10):985-6; author reply 986-7. PubMed ID: 20859182
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of caspofungin versus liposomal amphotericin B in the treatment of systemic fungal infections: a systematic review of economic analyses.
Mistro S; Rosa L; Gomes B; Miranda L; Badaró R
Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):465-73. PubMed ID: 27322156
[TBL] [Abstract][Full Text] [Related]
14. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
Ellis M; Frampton C; Joseph J; Alizadeh H; Kristensen J; Hauggaard A; Shammas F
J Med Microbiol; 2006 Oct; 55(Pt 10):1357-1365. PubMed ID: 17005784
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
[TBL] [Abstract][Full Text] [Related]
16. Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
Barnes R; Earnshaw S; Herbrecht R; Morrissey O; Slavin M; Bow E; McDade C; Charbonneau C; Weinstein D; Kantecki M; Schlamm H; Maertens J
Clin Ther; 2015 Jun; 37(6):1317-1328.e2. PubMed ID: 25891805
[TBL] [Abstract][Full Text] [Related]
17. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.
Cagnoni PJ; Walsh TJ; Prendergast MM; Bodensteiner D; Hiemenz S; Greenberg RN; Arndt CA; Schuster M; Seibel N; Yeldandi V; Tong KB
J Clin Oncol; 2000 Jun; 18(12):2476-83. PubMed ID: 10856108
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis.
Wingard JR; Wood CA; Sullivan E; Berger ML; Gerth WC; Mansley EC
Clin Ther; 2005 Jun; 27(6):960-9. PubMed ID: 16117996
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]